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Abstract
Objective—The pathophysiology of osteonecrosis of the jaw (ONJ) is thought to be linked to
suppression of intracortical remodeling. Aim of this study was to determine whether mice, which
normally do not undergo appreciable amounts of intracortical remodeling, could be stimulated by
ovariectomy to remodel within the cortex of the mandible and if bisphosphonates (BPs) would
suppress this intracortical remodeling.
Material and Methods—Skeletally mature female C3H mice were either ovariectomized
(OVX) or SHAM operated and treated with two intravenous doses of zoledronic acid (ZOL, 0.06
mg/kg body weight) or vehicle (VEH). This ZOL dose corresponds to the dose given to cancer
patients on a mg/kg basis, adjusted for body weight. Calcein was administered prior to sacrifice to
label active formation sites. Dynamic histomorphometry of the mandible and femur were
performed.
Results—Vehicle-treated OVX animals had significantly higher (8-fold) intracortical remodeling
of the alveolar portion of the mandible compared to sham – this was significantly suppressed by
ZOL treatment. At all skeletal sites, overall bone formation rate (BFR) was lower with ZOL
treatment compared to the corresponding VEH group.
Conclusions—Under normal conditions the level of intracortical remodeling in the mouse
mandible is minimal but in C3H mice can be stimulated to appreciable levels with ovariectomy.
Based on this, if the suppression of intracortical remodeling is found to be part of the
pathophysiology of ONJ, the ovariectomized C3H mouse could serve as a useful tool for studying
this condition.
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CLINICAL RELEVANCE
Osteonecrosis of the jaw is a rare but serious side effect of bisphosphonate treatment. The
pathophysiology of this condition remains unclear due in part to the absence of an animal
model. A key factor in the etiology of the condition is thought to be suppression of
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intracortical remodeling. We show here for the first time that the mandible of mice can be
stimulated to undergo intracortical remodeling by ovariectomy and this increased
remodeling is suppressed with bisphosphonates. These results suggest this mouse strain
may be useful in the development of an animal model for osteonecrosis of the jaw.
Introduction
Bisphosphonates (BPs) are a drug class that is widely and effectively used in the treatment
of osteoporosis, Paget's disease and metastatic cancers involving bone. BPs are associated
with a rare condition known as osteonecrosis of the jaw (ONJ) (1,2). Zoledronic acid
(Zometa), the BP most often used in treating cancer patients, is most often associated with
ONJ. This condition is characterized by regions of exposed, necrotic bone in the mandible
and/or maxilla (3,4). Unfortunately, little is known about the pathogenesis of ONJ due in
part to the absence of an animal model for this condition (3,5).
The mandible undergoes intracortical remodeling at a faster rate than other cortical bone
regions in the body (6,7). Many have suggested that ONJ is related to remodeling
suppression (1,5). Consistent with this theory, BPs have been shown to impart near complete
suppression of intracortical remodeling in the mandible of beagle dogs (7) and this is
associated with an accumulation of necrotic bone matrix (6).
Unlike humans and other larger animals, rodents do not routinely undergo appreciable
amounts of intracortical remodeling (8). This potentially limits the use of rats and mice as an
animal model for ONJ, if suppression of intracortical remodeling is a part of the disease
etiology. Recent data have documented that adult C3H mice undergo significant amounts of
intracortical remodeling in the femur mid-diaphysis following ovariectomy (9). Whether or
not similar increases in intracortical remodeling occur in the mandible following OVX is not
clear. If they do, it's possible this mouse strain could be valuable as a model to study ONJ.
Therefore, the goal of this study was to determine whether or not the C3H mouse undergoes
significant intra-cortical bone remodeling in the mandible following ovariectomy. We
hypothesized that the mandible of C3H mice would undergo higher levels of intracortical
remodeling with ovariectomy and that intravenous zoledronic acid would suppress this
increased remodeling.
Materials and Methods
Skeletally-mature female C3H mice (n=33) were obtained from Harlan at 16 weeks of age
and divided into two groups; ovariectomized (OVX, n=17) and SHAM operated (n=16).
Within each group, some of the animals were treated with zoledronic acid (ZOL) and the
remaining animals were treated with physiologic saline vehicle (VEH). Ovariectomy
surgeries were performed at Harlan, where the mice were housed for 7 days post-OVX prior
to shipment to IU School of Medicine (IUSM) were they were housed 7 days prior to any
intervention. Animals were housed four per cage (within treatment group) in the LARC
facility and monitored daily for general health and any abnormal effects of treatment. All
animal procedures were approved prior to the study by the IUSM Animal Care and Use
Committee.
Animals in the ZOL treatment group received the drug via intravenous infusion at weeks 3
and 6 post-OVX. ZOL concentrations were based on the 4mg drug dose given to cancer
patients assuming a 60kg individual, adjusted on a mg/kg basis (0.06 mg/kg body weight
dissolved in 0.2 mL sterile saline). VEH animals received 0.2 mL IV physiologic saline
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vehicle at the same time points as ZOL treatment. All IV infusions were administered
through the tail vein using a 27 gauge needle over a 3-5 minute period while the animal was
contained within an animal restrainer. Calcein (0.2 ml/kg @ 30mg/kg) was administered
intraperitoneally at 14 and 4 days prior to sacrifice to label active formation sites. The
animals were euthanized at 24 weeks of age (CO2 inhalation with death confirmed by
inducing bilateral pneumothorax). The mandibles and femurs were collected at necropsy and
fixed in 10% neutral buffered formalin. The absence/presence of ovaries was confirmed at
necropsy.
Histology
Mandible and femoral tissues were processed undecalcified for histological analyses using
standard methods (10). To determine if any bone matrix necrosis existed in these tissues, all
specimens were stained with 1% basic fuchsin dissolved in increasing ethanol
concentrations (70%, 95%, and 100%) each for 4 hours (6). Mandibles were sectioned
(∼100um thick) throughout the molar region by making successive buccal-lingual cuts in the
frontal plane using a diamond wire saw (Histosaw; Delaware Diamond Knives) (Figure 1).
Femurs were sectioned (∼100um thick) at the mid-diaphysis.
Histological measurements were made using a semiautomatic analysis system (Bioquant
OSTEO 7.20.10, Bioquant Image Analysis Co.) attached to a microscope (Nikon Optiphot 2
microscope, Nikon) with a fluorescent light source. For the mandible, dental landmarks were
used to choose one section for analysis at a similar rostral/caudal region among all animals.
Specifically, we chose the section that contained the deepest root of the first molar tooth as
this provided us the opportunity to assess the greatest amount of alveolar bone in our
analysis. This method of section selection was chosen in order to provide consistency in the
anatomy of the section across all animals. For the mandible sections, data were collected
separately for alveolar cortical bone (defined as cortical bone above the most distally
observed portion of the tooth root) and the non-alveolar cortical bone (the cortical tissue
inferior to the apex of the tooth root) (Figure 1). In the alveolar mandible, the total surface of
bone immediately adjacent to the tooth root where attachment of the periodontal ligament
occurs was measured for the amount of calcein labeling (Figure 1). In addition to the cortical
bone of the non-alveolar mandible, the trabecular bone surfaces (found just below the apex
of the molar) were also measured for amount of calcein labeling within the region of
interest. The cortical bone of the entire cross section of femur was assessed for intracortical
bone label.
For measures of intracortical remodeling, total bone area (B.Ar), number of labeled osteons
(L.On.#, osteons with either single or double label), the total length of osteon labeled surface
(LS), and the mean inter-label distance (Ir.L.Wi) were determined. Osteons were defined as
structures within the cortical bone that contained single or double label (Figure 2A, 2B), –
resorption spaces without label were not counted in this analysis. For surface-based
assessments total bone surface (BS), surfaces with either single or double label (sLS and
dLS, respectively) and Ir.L.Wi were measured. As calcein labels were injected on two
different occasions, measurements are separately for surfaces having single label surface
(indicative of active bone formation at one of the two times of calcein injection) and double
label surface (indicative of active bone formation at both times of calcein administration).
Mineral apposition rate (MAR, um/day) was calculated as Ir.L.Wi / 10, where 10 is the
number of days between labels. Intra-cortical bone formation rate (BFR, %/year) was
calculated as (MAR × (LS/2) / B.Ar × 100) × 365. Surface-based mineralizing surface (MS/
BS, %) was calculated as ((0.5 * sLS) + dLS)/BS)*100. Surface-based bone formation rate
(BFR, um3/um2/year) was calculated as MAR * (MS/BS/100) * 365. For animals with only
singly labeled osteons, a value of 0.3 was used for MAR (11); if no label was present, MAR
was considered to be a missing value and BFR was considered to be 0 to reflect the absence
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of any bone formation activity. All measures and calculations are in accordance with
ASBMR recommended standards (12).
Statistics
All statistical analyses were performed using SAS statistical software (SAS Institute, Inc.).
Two-way ANOVA tests were used to determine the main effects of surgery (SHAM versus
OVX) and treatment (VEH versus ZOL) as well as their interaction. Significant interactions
were further assessed by one-way ANOVA to determine specific group differences. Post-
hoc comparisons were made using Fisher's PLSD tests. For all tests, p < 0.05 was used to
determine statistical significance.
Results
Bone Matrix Necrosis
No areas of bone matrix necrosis were noted in either the mandible or femur of any animal.
This assessment consisted of examining five cross-sections of the mid-diaphysis femur and
between 8 and 15 sections of mandible for each animal.
Mandible: Alveolar and Non-alveolar Cortical Bone
In the alveolar bone of the mandible, there was no significant difference in intracortical
MAR or labeled osteon number among the four treatment groups (Table 1). There was a
significant interaction between surgery and treatment for alveolar bone BFR (Table 1 and
Figure 3A). In VEH-treated animals, BFR was significantly higher in OVX (>7-fold)
compared to SHAM while in ZOL-treated animals BFR was 75% lower in OVX compared
to SHAM. There was no significant difference between VEH-SHAM and ZOL-SHAM. In
the non-alveolar cortical bone of the mandible there was no significant difference in any of
the parameters measured among groups (Table 1).
Mandible: Periodontal Ligament & Trabecular Bone Surfaces
On the periodontal ligament attachment surface of the alveolar cortical bone there was no
significant effect of surgery, drug treatment or an interaction between the two interventions
for MAR, MS/BS or BFR (Table 2). On the trabecular bone surfaces of the mandible, there
were significant effects of both surgery and ZOL treatment (Table 2). Trabecular MS/BS
showed both a significant surgery and treatment effect with no significant interaction
between the main effects. ZOL-treated animals had a 59% lower MS/BS and a 58% lower
BFR compared to VEH-treated animals (Table 2 and Figure 3B).
Tooth Dentin Mineralization Rate
During our measures of calcein labeling in the mandible, we observed clear and consistent
double calcein labeling within the incisor tooth dentin (Figure 2A). We therefore measured
mineral apposition rate to determine if there was any effect of either surgery or treatment in
dentin mineralization rate. There was no significant difference due to surgery or ZOL-
treatment on dentin MAR (Table 2).
Femur
Femoral intracortical bone parameters were all significantly affected by ZOL-treatment, but
not surgery. There was also no interaction between the two interventions. MAR and labeled
osteon number were both significantly lower in ZOL-treated animals compared to VEH
(-27% and -37%, respectively). These changes combined to produce a significantly lower
intracortical BFR (-65%) in ZOL compared to VEH treated animals (Table 3 and Figure
3C).
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Discussion
For several years now, bisphosphonates have been linked to ONJ (1,2). Although recent
studies have emerged showing potential models of ONJ in mice (13), rats (14-20), and dogs
(21,22), there remains no clear animal model that parallels ONJ etiology and
pathophysiology. The most prominently proposed mechanism for ONJ involves remodeling
suppression. This hypothesis, as opposed to a specific effect of bisphosphonates on the bone/
soft tissue, is further supported by the recent case reports of ONJ in patients treated with
denosumab (23). Denosumab, a human monoclonal antibody that inhibits osteoclast
development by targeting RANK ligand acts through a different mechanism than
bisphosphonates and does not accumulate in the skeleton. One prominent similarly between
bisphosphonates and denosumab is that they both significantly suppress of bone remodeling.
It is generally accepted that rodents do not naturally undergo significant amounts of
intracortical remodeling in their long bones or the mandible (8) and therefore their utility as
a model for ONJ has been questioned (24,25). Previously, Li et al (9) have shown that
ovariectomy in C3H mice elicits a significant increase in intracortical remodeling of the
femur. Our study expands this work by showing that intracortical remodeling occurs also
within the mandible, specifically within the alveolar portion, of C3H mice following
ovariectomy. In VEH treated animals, we showed over a 7-fold higher alveolar BFR due to
OVX compared to SHAM operated animals. Consistent with the low, but measurable
intracortical alveolar BFR in our SHAM group, osteons were noted in the mandible/maxilla
of 17 week old C3H mice although these existed in only some animals and were low in
number (26). Our study also documents that ZOL-treatment prevented the OVX-induced
elevation in intracortical remodeling of the alveolar cortical bone. This is consistent with the
suppression of intracortical remodeling at various sites in humans (27,28) and in the alveolar
bone of dogs (6,7).
Histomorphometry is the gold-standard method for assessment of bone remodeling.
Although other methods, such as serum or urine biomarkers can provide whole body
estimates of remodeling, only histology can provide site-specific remodeling data. In the
current work, we used the standard technique of fluorochrome labeling to denote actively
forming bone surfaces. By injecting calcein, which binds to calcium being incorporated into
hydryoxyapatite during mineralization, it is possible to determine parameters such as
mineral apposition rate (the rate at which bone is formed at an individual site), mineralizing
surface (the number of actively forming surface), and bone formation rate (the rate bone is
forming at a tissue-level). As mature animals predominantly undergo remodeling (the
coupled process of resorption and formation) on trabecular surfaces and exclusively undergo
remodeling within the cortex, assessment of bone formation rate in these bone envelopes
gives insight into the rate of remodeling. As formation-based modeling occurs on
periodontal ligament surfaces, BFR on this surface is directly related to osteoblast-mediated
bone formation.
The effect of ZOL was also evident in the current study by the lower remodeling of the
mandible trabecular bone, with ZOL-treated animals having a 42% lower BFR compared to
VEH. We did not find a significant difference in OVX versus SHAM animals for trabecular
BFR. Previous work has shown that the OVX-induced increase in remodeling in rodents
occurs acutely but is then lost over time (29). Thus it's possible that our assessment eight
weeks post-ovariectomy missed the period when BFR was stimulated. Alternatively its
possible that the response to ovariectomy differs in this trabecular bone in the mandible
compared to more traditionally assessed sites (vertebra or proximal tibia).
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The surface adjacent to the periodontal ligament primarily undergoes bone modeling (30).
We found no significant effect of either surgery or drug-treatment on this surface. Recent
reports from our lab have shown that bisphosphonates, including ZOL, do not affect
formation bone modeling in ovariectomized animals (31). Previous work in B6 mice showed
ZOL significant suppressed mandible periosteal surface bone formation rate, a surface that
also primarily undergoes modeling activity (32). The discrepancy between these previous
data and the current study are not clear although it's likely due to either the differences in
mouse strain (B6 versus C3H) or the ZOL dosing schedule. The current study administered
two doses ZOL while the previous study administered weekly ZOL (9 total doses); it's
possible that these higher doses could produce a suppressive effect on osteoblast activity.
In accordance with Li et al. (9), our study showed a 27% higher intracortical BFR in the
femur of OVX-VEH compared to SHAM-VEH although this was not statistically
significant. The discrepancy between the previous and current work could be the result of
the technique used to assess intracortical remodeling where Li et al counted both labeled
osteons and resorption spaces while we excluded the latter. We opted to only assess labeled
osteons to provide the most conservative assessment of intracortical activity as there existed
regions in the mandible in which distinguishing between an unlabeled resorption space and a
trabecular surface proved difficult. Intracortical remodeling of the femur was significantly
reduced with ZOL treatment, consistent with studies in larger animals treated with either
ZOL or other bisphosphonates (7,33).
In both the femora and mandibles, prior to sectioning, all specimens were stained en bloc
with basic fuchsin to elucidate regions of bone matrix necrosis, defined as regions of bone
devoid of stain, demarcating regions of non-viable bone (34,35). No regions of bone matrix
necrosis were noted in this study, likely due to the short treatment duration. We have
previously shown significant accumulation of necrotic matrix existed within the mandible of
beagle dogs treated for 1 or 3 years of daily oral alendronate (6,22) yet not in animals treated
for 3 or 6 months (7). This suggests a time-dependent factor in the development of matrix
necrosis which makes some sense as the region would need to have time for the local
canalicular network to fill with mineral. We hypothesize that longer duration of
bisphosphonate treatment following ovariectomy in this mouse strain would result in
accumulation of necrotic bone matrix.
Nearly 20 years ago, prolonged treatment with clodronate in young growing rats was shown
to produce necrotic bone fragments projecting through the oral mucosa (20). More recently,
several publications have suggested ONJ can be produced in rodents. These studies have
involved mainly treatment of rats with high dozes of ZOL with or without concominant
treatment with dexamethasone or dental surgery (14-16,18). One study in B6 mice, has also
shown ZOL and/or dexamethasone combined with tooth extraction revealed ONJ-like
lesions (13). Although these rodent models necessitate further validations, the emerging
evidence suggests the rodent may serve as an important animal model for studying ONJ.
Unfortunately none of these studies assessed intracortical bone remodeling. Significant
suppression of intracortical remodeling and formation of exposed bone and sequestra has
been recently documented in beagle dogs treated with zoledronic acid and subjected to
dental extraction (21).
Conclusion
In conclusion, we show that ovariectomy of skeletally mature C3H inbred mice stimulates
intracortical remodeling in the mandible, especially in the alveolar region. Furthermore, we
show that bisphosphonate treatment significantly suppresses this intracortical remodeling. If
suppression of intracortical remodeling proves to be important in the etiology of
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osteonecrosis of the jaw then the ovariectomized C3H mouse may prove useful as an animal
model to study this condition.
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Figure 1.
Region of assessment in mouse mandible. Upper panel is a photograph of the mouse
hemimandible showing molar region where histological sections were obtained. Lower
panel shows a CT image (for illustration purposes only, no CT was done in this study) of the
region similar to that assessed histologically. The line at the base of the tooth root separates
the alveolar from the non-alveolar bone, the two regions of intracortical bone analyses.
Arrows show the periodontal ligament bone surface on which assessment of calcein labeled
surface was made. The box represents the region for trabecular bone analyses.
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Figure 2.
Photomicrograph of basic fuchsin-stained mandible (A) and femur (B) viewed with
fluorescent light. Insets show actively remodeling intracortical osteons. Dotted arrows in (A)
show the periodontal ligament bone surface on which assessment of calcein labeled surface
was made; solid arrows show the location of dentin mineral apposition rate measures.
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Figure 3.
Ovariectomy stimulates and zoledronic acid (ZOL) reduces remodeling activity in C3H
mouse. (A) In alveolar cortical bone of the mandible, vehicle (VEH) treated ovariectomized
(OVX) animals had >7-fold higher bone formation rate (BFR) compared to SHAM and this
was significantly suppressed by ZOL. (B) Trabecular bone of the mandible showed ZOL-
treated animals had a 58% lower BFR compared to VEH. (C) Femur intracortical
remodeling was significantly suppressed in ZOL-treated animals compared to VEH treated
animals. Data presented as mean + SE. p < 0.05 vs. Sham within treatment (a), within
surgery between drug (b).
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